SG2918 is a first-in-class ADC with potential of eliminating immunosuppressive cells and activating tumor immune response. It has demonstrated phenomenal anti tumor activities in both monotherapy and combo treatment with ICIs such as PD-1 inhibitor. SG2918 has received IND clearance from NMPA and a Ph I clinical trial for the treatment of late stage solid tumor is ongoing in China.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
